The FDA has approved a new Alzheimer's drug from Eli Lilly called Kisunla, shown in clinical trials to modestly slow memory and thinking decline in those with the disease. The drug, a monoclonal antibody infusion, targets amyloid in the brain, a hallmark of Alzheimer's. This approval adds to treatment options with comparable results to a similar drug, Leqmebi. The drug is intended for adults with mild cognitive impairment or early Alzheimer's. Results from a 1,700-person trial showed a 35% slowdown in disease progression after 18 months. Though potentially life-threatening side effects exist, Medicare is expected to cover the $32,000 12-month supply. Patient testimonials, such as 79-year-old Pat Bishara, highlight the positive impact of the treatment. The drug represents a significant step in addressing the devastating impact of Alzheimer's, as the number of affected Americans is expected to nearly double by 2060.